Is Troponin Elevation After TAVR Related to Mortality?

Troponins have long had diagnostic value not only for infarction. Their ability to predict mortality is well established for all cardiac conditions. Moreover, it has been demonstrated in all critically ill patients, including patients with COVID-19, regardless of the triggering condition.

¿La elevación de troponinas post TAVI tiene relación con la mortalidad?

While their significance in COVID cases is backed by the literature, there was not a robust publication addressing this phenomenon in relation with transcatheter aortic valve replacement (TAVR). This research investigated whether troponin elevation after TAVR is related to mortality, and it sought to determine a threshold.

The study included 1333 consecutive patients who underwent TAVR and had troponin values available.

A relevant injury after TAVR was defined as >18.3-fold increase of troponins compared with the baseline value. This association remained significant at 30 days and at 2 years, after adjusting for all confounding variables (hazard ratio [HR]: 1.90; 95% confidence interval [CI]: 1.40 to 2.57; p < 0001).


Read also: First Guidelines Focused Specifically on Chest Pain Management.


Certain subgroups also experienced mortality rates that were twice as high; examples included patients with coronary artery disease (HR: 2.17; p < 0.001), renal failure (HR: 2.17; p < 0.001), and intermediate or high surgical risk (HR: 2.70; p = 0.003).

Conclusion

This study determined that a 20-fold troponin elevation from the baseline value serves as a threshold for predicting mortality after transcatheter aortic valve replacement.

tropo-y-TAVI

Original Title: Postprocedural Troponin Elevation and Mortality After Transcatheter Aortic Valve Implantation.

Reference: Matthias Schindler et al. J Am Heart Assoc. 2021 Oct 29;e020739. Online ahead of print. doi: 10.1161/JAHA.120.020739.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

More articles by this author

Severe Tricuspid Regurgitation: Surgical vs. Transcatheter Edge-to-Edge Repair

While highly prevalent, tricuspid regurgitation is a notably undertreated valvulopathy. Its progression has been associated with higher mortality and significant disability. According to the...

ACCESS-TAVI: Comparing Post TAVR Vascular Closure Devices

Transcatheter aortic valve replacement (TAVR) is a well-established option to treat elderly patients with severe symptomatic aortic valve stenosis. Technical advances and device development...

Coronary Artery Disease in Aortic Stenosis: CABG + SAVR vs. TAVR + PCI: Data from Spanish Centers

Multiple randomized studies have shown comparable or superior efficacy of transcatheter aortic valve replacement (TAVR) vs. coronary artery bypass graft (CABG).  However, many of...

TCT 2024 | TRISCEND II: A New Hope in Percutaneous Tricuspid Valve Replacement

Advanced tricuspid regurgitation (TR) is a debilitating disease associated with heart failure and increased mortality.  Edge-to-edge repair has been shown to improve both clinical condition...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

Severe Tricuspid Regurgitation: Surgical vs. Transcatheter Edge-to-Edge Repair

While highly prevalent, tricuspid regurgitation is a notably undertreated valvulopathy. Its progression has been associated with higher mortality and significant disability. According to the...

ACCESS-TAVI: Comparing Post TAVR Vascular Closure Devices

Transcatheter aortic valve replacement (TAVR) is a well-established option to treat elderly patients with severe symptomatic aortic valve stenosis. Technical advances and device development...

Endovascular Treatment of Iliofemoral Disease for the Improvement of Heart Failure with Preserved Ejection Fraction

Peripheral artery disease (PAD) is a significant risk factor in the development of difficult-to-treat conditions, such as heart failure with preserved ejection fraction (HFpEF)....